Vertex Pharmaceuticals VRTX Net payments due to CRISPR Therapeutics AG related to finite-lived intangible assets
Net payments due to CRISPR Therapeutics AG related to finite-lived intangible assets at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept vrtx:NoncashFinancingOrInvestingActivitiesCollaborativeArrangementMilestonePaymentsDue.
The official record: Vertex Pharmaceuticals’s 10-K, filed February 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's net payments due to crispr therapeutics ag related to finite-lived intangible assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's net payments due to CRISPR therapeutics AG related to finite-lived intangible assets?
- Vertex Pharmaceuticals (VRTX) reported net payments due to CRISPR therapeutics AG related to finite-lived intangible assets of $0 in Q4 2025.
- What does net payments due to CRISPR therapeutics AG related to finite-lived intangible assets mean?
- Non-cash payments or obligations related to intangible asset acquisitions.
- How do you interpret net payments due to CRISPR therapeutics AG related to finite-lived intangible assets?
- Indicates the scale of strategic investments or partnerships that are structured through non-cash consideration, such as equity or milestone-based obligations.
- How does net payments due to CRISPR therapeutics AG related to finite-lived intangible assets compare across companies?
- Common in biotech and pharma for R&D collaborations; specific to companies with heavy reliance on external innovation.